CDCP1 and prostate carcinoma: In primary and metastatic castration-resistant prostate cancer tissues, CBP/p300 are over expressed at mRNA levels.386 CBP/p300 has firmly been established to act as transcriptional co-activators of androgen receptor (AR).387 p300 has been documented to interact directly with AR N-terminal domain and AR-Ligand binding domain.388 Upon interaction, CBP/p300 acetylates AR and promotes AR stability.389 Ji et al.390 reported that CUB-domain-containing protein 1 (CDCP1) is highly expressed in late-stage and castrate-resistant prostate cancer (CRPC).